Parkinson’s Disease: A Digital Biomarker Platform for Differentiated Diagnosis
2024年7月2日 - 5:00PM
ビジネスワイヤ(英語)
- BrainTale was attending the 10th Congress of the European
Academy of Neurology (EAN) to unveil the results of its 189
subjects' study with parkinsonian symptoms.
- In an oral presentation, the medtech demonstrates the value of
its digital biomarker platform in the differential diagnosis of
parkinsonian syndromes.
BrainTale, a medtech deciphering white matter to enable
better brain care, spin-off of the Paris Region Greater
Hospitals, attended the European Academy of Neurology (EAN)
congress held in Helsinki, Finland, from June 29 to July 02, 2024.
Data presented during the oral presentation by Vincent Perlbarg,
co-founder and scientific director, and Martin Grange, data
scientist, demonstrated the potential of BrainTale's solution to
specifically differentiate Parkinson's disease (PD) from other
conditions with close clinical features, such as Multisystem
Atrophy (MSA) or Progressive Supranuclear Palsy (PSP).
Affecting around 5 million people worldwide, Parkinson's disease
diagnostic and care remain major challenges. Confirmation of
diagnostic is complex, notably due to the overlap of clinical
symptoms with other neurodegenerative disorders. Even though a
non-invasive and reliable differential diagnosis could be possible
based on the data presented. Indeed, since inception, BrainTale has
been developing non-invasive, accessible, actionable and clinically
validated measurement and prediction tools for patients suffering
from brain diseases.
The oral communication "Differential diagnosis model in
parkinsonian syndromes derived from calibrated diffusion tensor
imaging" highlighted the 189 parkinsonian symptoms subjects’ study
from three different prospective trials, including 92 PD patients,
45 MSA patients and 42 PSP patients. Data from each patient were
automatically processed to provide DTI parameters. From these, a
supervised learning classification model was tested by receiver
operating function (ROC) analysis. The model achieved a mean area
under the ROC curve of 0.87 ± 0.05, a mean specificity of 0.74 ±
0.10 and a mean sensitivity of 0.90 ± 0.07.
These data highlight the sensitivity of white matter markers
provided by BrainTale for developing an efficient and robust
classification of parkinsonian syndromes, more specifically,
differentiating PD vs MSA and PSP, two frequent confusing
syndromes.
"The easy access to diffusion tensor markers in the clinical
setting with BrainTale's platform paves the way for improving
differential diagnosis and accelerating treatment development,"
comments professor Stéphane Lehéricy, Neuroradiologist at Paris
Region Greater Hospitals and Director at the Brain Institute. "This
technology also enables us to better understand the pathophysiology
of different diseases and facilitates patient care in a
non-invasive and reliable way" he adds.
About BrainTale
BrainTale is an innovative European medtech company measuring
the brain through white matter quantification and standardization
based on a commercially available software medical device solution.
This regulatory-cleared AI software offers quality controlled,
non-invasive, reliable and clinically validated reports after
diffusion tensor MRI data processing. BrainTale enables drug
developers, leading academic researchers and physicians to improve
patient care by understanding neuroinflammatory and
neurodegenerative conditions, assess brain lesions evolutions and
take appropriate decisions in the clinic and during drug
development. BrainTale empowers the scientific and medical
community with objective measure to transform brain care.
Because brain diseases have become the medical issue of our
time, we can no longer wait. At BrainTale, we strongly believe that
by exploring better, we can treat faster, together.
For more information, please visit www.braintale.eu
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702099222/en/
BrainTale – Lisa Marcheval, communication manager,
lisa.marcheval@braintale.eu Press relations: Anna Casal,
casal.anna@gmail.com, +33650615571